Navigation Links
Heptares to Present at Upcoming Scientific and Biotech Industry Conferences
Date:4/16/2013

WELWYN GARDEN CITY, England and BOSTON, April 16, 2013 /PRNewswire/ --

Heptares Therapeutics, the leading GPCR drug discovery company, notes that it will be presenting at the following scientific conferences and biotech industry events over the coming weeks.

8th Annual Drug Discovery Chemistry (San Diego, CA, USA, April 16-18)

Dr Rob Cooke , Heptares' Head of Biomolecular Structure, will give a presentation entitled "Utilizing Structural Insights in GPCR Drug Discovery" as part of the GPCR-Based Drug Design stream (2:40pm, 17 April). Dr Cooke will also be hosting an evening workshop on "Practical Aspects of Structure-based Drug Discovery with GPCRs" at the meeting.

2013 BIO International Convention (22-25 April, Chicago, IL, USA)

Mr Dan Grau (President) will present an overview of the Company during the BioBusiness Forum, which takes place from 8:00am-11:00am on 24 April. Dr Barry Kenny (Chief Business Officer) and Dr Cath Hutchings (Antibody Discovery & Strategic Partnering) will also be present at the event.

4th GPCR Colloquium  at The American Society for Pharmacology and Experimental Therapeutics (ASPET) meeting (Boston, MA, USA, 24-25 April)

Dr Fiona Marshall , Heptares' Chief Scientific Officer, will present a talk entitled "X-ray Structures for the Predictive Generation of GPCR Drugs" (2:15pm, 25 April).

6th Annual Diabetes Summit (29-30 April, Boston, MA, USA)

Mr Dan Grau , Heptares' President, will participate in two panel discussions as part of the Diabetes Partnering and Deal Making stream: the panels are entitled "Innovative Partnering & Licensing Strategies" (3:30pm, 29 April) and "Type 2 Diabetes Innovation" (10:20am, 30 April).

Gordon Research Conference on Molecular Pharmacology (28 April-3 May, Lucca, Italy)

Dr Kaspar Hollenstein , Senior Scientist at Heptares, will give a presentation entitled "Using Thermostabilized Receptors to Obtain Crystal Structures of Family A and Family B G protein-coupled Peptide Receptors" (7:00pm, 1 May).

For a full list of events at which Heptares will be present, please visit http://www.heptares.com

About Heptares Therapeutics

Heptares creates new medicines targeting clinically important, yet historically challenging, GPCRs (G protein-coupled receptors), a superfamily of drug receptors linked to a wide range of human diseases. Leveraging our advanced structure-based drug design technology platform, we have built an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including Alzheimer's disease, Parkinson's disease, schizophrenia, migraine and diabetes. Our pharmaceutical partners include Shire, Cubist, Takeda, MorphoSys, AstraZeneca and MedImmune, and we are backed by MVM Life Science Partners, Clarus Ventures, Novartis Venture Fund and Takeda Ventures. To learn more about Heptares, please visit http://www.heptares.com.


'/>"/>
SOURCE Heptares Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders
2. Heptares Solves First Family B GPCR Structure
3. Heptares to Present at BIO-Europe 2012
4. Heptares to Moderate Panel on Rare Diseases at BBC New York CEO Meeting (13-14 February)
5. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
6. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
7. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
8. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
9. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
10. Masimo to Present at 23rd Annual Piper Jaffray Health Care Conference
11. Biocept and Academic Collaborators to Present Posters at San Antonio Breast Cancer Symposium on Circulating Tumor Cells (CTCs)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... ... ... The award-winning producers behind the American Farmer series proudly ... at helping farmers solve the problem of nitrogen loss. The upcoming episode is ... RFD-TV. Check your local listings for more info. , As a global ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... Huron Digital Pathology , a provider of whole slide imaging solutions, are ... conference . The workshop, entitled “Successfully Deploying a Best-in-Class Strategy for Digital Pathology,” ...
(Date:9/20/2017)... Aurora, Ohio (PRWEB) , ... September 20, 2017 ... ... automation, systems integration, and building management solutions, announced today the opening of an ... customers in Taiwan and the Greater China region, while developing new relationships in ...
(Date:9/19/2017)... Poway, CA (PRWEB) , ... September 19, 2017 , ... VetStem Biopharma ’s CEO ... H. Riordan PA, PhD in Riordan’s new book "Stem Cell Therapy: A Rising Tide". ... past 14 years. They bonded over an interest in the potential of stem cell ...
Breaking Biology Technology:
(Date:4/11/2017)... 11, 2017 Crossmatch®, a globally-recognized leader ... today announced that it has been awarded a ... Activity (IARPA) to develop next-generation Presentation Attack Detection ... "Innovation has been a driving force within Crossmatch ... allow us to innovate and develop new technologies ...
(Date:4/6/2017)... Forecasts by Product Type (EAC), ... End-Use (Transportation & Logistics, Government & Public Sector, Utilities ... Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), ... you looking for a definitive report on the $27.9bn ... ...
(Date:4/4/2017)... NEW YORK , April 4, 2017   ... solutions, today announced that the United States Patent and ... The patent broadly covers the linking of an iris ... the same transaction) and represents the company,s 45 th ... our latest patent is very timely given the multi-modal ...
Breaking Biology News(10 mins):